Şirket yükleniyor
Just reported
Q3 2026 results
From Biogen's results release of 28 Ekim 2026; its quarterly report has since been filed.
Revenue
Actual
$2,8B
+%11 y/y
+%2,5 q/qGuided
—
No guide given
EPS, GAAP
Actual
-$0,14
Guided
—
No guide given
Company outlook
Full year 2026
- EPS, adjusted$12,20 – $13,00First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Biogen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company$1,36TA+
JNJJohnson & Johnson$688,6BA+
MRKMerck & Co., Inc.$364,3BA
NVSNovartis AG$306,3BA
AMGNAmgen Inc.$251,9BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 Eki 2026CBGraded C, now B
MCKMckesson Corporation4 Kas 2026BAGraded B, now A
CVSCVS Health Corp4 Kas 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 Kas 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 Eki 2026CAGraded C, now A
Nasıl para kazanıyor
- Sales of prescription medicines%72
- Anti-CD20 medicine royalties and profit shares%18
- Contract manufacturing, royalties and related revenue%8
- Alzheimer’s medicine collaboration%2
Gelir payları nine months ended September 30, 2026 dönemi için tahmindir; resmî bir bildirimden alınmış rakamlar değildir.
Rekabet ettiği şirketler
Ne satıyor6
SPINRAZA
An injected medicine for spinal muscular atrophy, a disease that causes muscle weakness.
TYSABRI
An infusion medicine for relapsing multiple sclerosis.
LEQEMBI
An antibody medicine for early Alzheimer’s disease, developed and sold with Eisai.
3 tane daha göster
SKYCLARYS
A medicine for Friedreich ataxia, an inherited disease that affects movement and coordination.
SYFOVRE
An eye injection for geographic atrophy, a disease that can cause central vision loss.
EMPAVELI
A medicine for a rare blood disorder and certain rare kidney diseases.
Kim alıyor4
- Wholesale distributors buy medicines in bulk for resale; a pair of distributors together accounted for 43.9% of gross product revenue (FY 2025, high).
- Specialty pharmacies and specialty distributors handle medicines that require specific storage, delivery or patient support.
- Hospitals, clinics and physicians prescribe or administer Biogen medicines and help patients obtain them.
- Government health programs and private insurers cover or reimburse the cost of many treatments.
Neye dayanıyor ve onu ne yıkabilir
Faaliyetin dayandığı şeyler
- 1Biogen relies on collaborators for some medicines’ development, manufacturing or sales, including Eisai, Ionis, Genentech, Supernus and Samsung Bioepis.
- 2A pair of wholesale distributors accounted for 43.9% of gross product revenue (FY 2025, high).
- 3Sales depend on regulatory approval, continued patent or other market protection, and coverage and reimbursement from government programs and private insurers.
Ters gidebilecekler
- 1Generic and biosimilar medicines, as well as newer competing treatments, can reduce sales or prices; generic versions of TECFIDERA and a biosimilar version of TYSABRI already compete with those products.
- 2Clinical studies can fail, take longer than planned or lead regulators to reject a medicine, limiting revenue from new products and additional uses of existing medicines.
- 3Changes to drug-price rules, insurance coverage or reimbursement can restrict patient access or lower the amount Biogen receives for its medicines.
Biogen Inc. hakkında
Biogen discovers, develops and sells medicines for neurological, immune-system and rare diseases. Its products include treatments for multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease and certain eye, kidney and blood disorders. It develops and commercializes some medicines with other drug companies, sharing costs, sales or profits under those agreements.
- Merkez
- Cambridge, Massachusetts
- Kuruluş
- 1978
- İşlem gördüğü borsa
- NASDAQ
- Mali yıl sonu
- December 31
Biogen Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.